Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Atezolizumab, Vinorelbine and Weekly Cyclophosphamide as T-cell Activators in First Line Metastatic Triple Negative Breast Cancer Patients Pre-treated With Anti-PD-L1/PD-1

NCT06690840 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT06690840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06690840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Atezolizumab, Vinorelbine and Weekly Cyclophosphamide as T-cell Activators in First Line Metastatic Triple Negative Breast Cancer Patients Pre-treated With Anti-PD-L1/PD-1
Lead sponsor
European Institute of Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
March 6, 2025
Completion date
February 15, 2027
Enrollment
45 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer